Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: Interaction with the renin-angiotensin system

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1262-1268

  Cameron, Norman E ^a   Cotter, Mary A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOOXIDATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; ENDONEURIUM; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCIATIC NERVE; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; MALE; NEURAL CONDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; SCIATIC NERVE;

EID: 0030432243     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. CALCUTT, N. A, MIZISIN, A. P. AND KALICHMAN, M. W.: Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. Eur. J. Pharmacol. 251: 27-33, 1994.
2. CAMERON, N. E. AND COTTER, M. A.: Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: Role of polyol pathway activity. Diabetologia 35: 1011-1019, 1992.
3. CAMERON, N. E. AND COTTER, M. A.: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab. Rev. 10: 189-224, 1994a.
4. CAMERON, N. E. AND COTTER, M. A.: Effects of evening primrose oil treatment on sciatic nerve blood flow and endoneurial oxygen tension in streptozotocin-diabetic rats. Acta Diabetol. 31: 220-225, 1994b.
5. CAMERON, N. E. AND COTTER, M. A.: Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats. Eur. J. Clin. Invest. 25: 19-24, 1995a.
6. CAMERON, N. E. AND COTTER, M. A.: Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J. Clin. Invest. 96: 1159-1163, 1995b.
7. CAMERON, N. E. AND COTTER, M. A.: Mechanisms underlying impaired peripheral nerve perfusion and endoneurial oxygenation in experimental diabetes: Potential treatment strategies. In Diabetic Neuropathy: New Concepts and Insights, ed. By N. Hotta, D. A. Greene, J. D. Ward, A. A. F. Sima and A. J. M. Boulton, pp. 3-15, Elsevier, Amsterdam, 1995c.
8. CAMERON, N. E, COTTER, M. A, ARCHIBALD, V, DINES, K. C. AND MAXFIELD, E. K.: Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37: 449-459, 1994c.
9. CAMERON, N. E, COTTER, M. A, DINES, K. C, MAXFIELD, E. K, CAREY, F. AND MIRRLEES, D. J.: Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 37: 651-663, 1994b.
10. CAMERON, N. E, COTTER, M. A. AND HOHMAN, T. C.: Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121,509, in streptozotocin-induced diabetic rats. J. Diabet. Complications 10: 43-53, 1996.
11. CAMERON, N. E, COTTER, M. A. AND LOW, P. A.: Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. Am. J. Physiol. 261: E1-E8, 1991.
12. CAMERON, N. E, COTTER, M. A. AND ROBERTSON, S.: The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Q. J. Exp. Physiol. 74: 917-926, 1989.
13. CAMERON, N. E., COTTER, M. A. AND ROBERTSON, S.: Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 35: 12-18, 1992.
14. CAMERON, N. E, DINES, K. C. AND COTTER, M. A.: The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 37: 1209-1215, 1994a.
15. COOPER, M. E, RUMBLE, J, KOMERS, R, HE-CHENG, D, JANDELEIT, K. AND SHEUNGTO, C.: Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 43: 1221-1228, 1994.
16. COTTER, M. A. AND CAMERON, N. E.: Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. Naunyn-Schmeideberg's Arch. Pharmacol. 351: 630-635, 1995.
17. COTTER, M. A, CAMERON, N. E. AND DINES, K. C.: Facilitation between the effects of polyol pathway inhibition and ω-6 essential fatty acid treatment on peripheral nerve function and blood flow in anaesthetized diabetic rats. J. Physiol. 483P: 141P-142P, 1995a.
18. COTTER, M. A, LOVE, A, WATT, M. J, CAMERON, N. E. AND DINES, K. C.: Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38: 1285-1294, 1995b.
19. 2 clearance curves used to measure blood flow in rat sciatic nerve. J. Physiol. 414: 35-54, 1989.
20. DINES, K. C, COTTER, M. A. AND CAMERON, N. E.: Comparison of the effects of evening primrose oil and triglycerides containing gamma-linolenic acid on nerve conduction and blood flow in diabetic rats. J. Pharmacol. Exp. Ther. 273: 49-55, 1995.
21. HUGHES, J. AND ROTH, R. H.: Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br. J. Pharmacol. 41: 239-255, 1971.
22. KAWAGUCHI, H, SAWA, H. AND YASUDA, H.: Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J. Mol. Cell Cardiol. 22: 839-842, 1990.
23. KIHARA, M. AND LOW, P. A.: Regulation of rat nerve blood flow: role of epineurial α-receptors. J. Physiol. 422: 145-152, 1990.
24. KIHARA, M. AND LOW, P. A.: Vasoreactivity to prostaglandins of rat peripheral nerve. J. Physiol. 484: 463-467, 1995a.
25. KIHARA, M. AND LOW, P. A.: Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp. Neurol. 132: 180-185, 1995b.
26. KIHARA, M., SCHMELZER, J. D, PODUSLO, J. F, CURRAN, F. F, NICKANDER, K. K. AND LOW, P. A.: Aminoguanidine effect on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicale. Proc. Natl. Acad. Sci. U.S.A. 88: 6107-6111, 1991.
27. KIHARA, M, ZOLLMAN, P. J, SMITHSON, I. L, LAGERLUND, T. D. AND LOW, P. A.: Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. Am. J. Physiol. 266: E980-E985, 1994.
28. LONGHURST, P. A. AND HEAD, R. J.: Responses of the isolated perfused mesenteric vasculature from diabetic rats: The significance of appropriate control tissues. J. Pharmacol. Exp. Ther. 235: 45-49, 1985.
29. LOW, P. A, LAGERLUND, T. D. AND MCMANIS, P. G.: Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int. Rev. Neurobiol. 31: 355-438, 1989.
30. MACLEOD, K. M.: The effect of insulin treatment on changes in vascular reactivity in chronic experimental diabetes. Diabetes 34: 1160-1167, 1985.
31. MAXFIELD, E. K, CAMERON, N. E. AND COTTER, M. A.: Increased vasa nervorum reactivity to noradrenaline in diabetic rats depends on reduced endothelium-dependent relaxation. Diabetic Med. 11: (Suppl. 2), P87, 1994.
32. MAXFIELD, E. K, CAMERON, N. E, COTTER, M. A. AND DINES, K. C.: Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats. Diabetologia 36: 1230-1237, 1993.
33. 1 receptor antagonist. Am. J. Physiol. 269: E530-E537, 1995.
34. MORFF, R. J.: Microvascular reactivity to norepinephrine at different arteriolar levels and durations of streptozocin-induced diabetes. Diabetes 39: 354-360, 1990.
35. REJA, A, TESFAYE, S, HARRIS, N. D. AND WARD, J. D.: Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabetic Med. 12: 307-309, 1995.
36. RUBANYI, G. M. AND POLOKOFF, M. A.: Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 46: 325-415, 1994.
37. SCOTT-BURDEN, T, RESINK, T. J, HAHN, A. W. AND VANHOUTTE, P. M.: Induction of endothelin secretion by angiotensin II: effects on growth and synthetic activity of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 17: (Suppl. 7), S96-S100, 1991.
38. A antagonist 5-(dimethylamino)-N-(3,4,-dimethyl-5-isoxazolyl)-1-napthalenesulfonamide. J. Med. Chem. 37: 329-331, 1994.
39. STEVENS, E. J. AND TOMLINSON, D. R.: Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br. J. Pharmacol. 115: 373-379, 1995.
40. TAKEDA, Y, MIYAMORI, I, YONEDA, T. AND TAKEDA, R.: Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci. 48: 2553-2556, 1991.
41. TAYLOR, P. D, MCCARTHY, A. L, THOMAS, C. R. AND POSTON, L.: Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br. J. Pharmacol. 107: 393-399, 1992.
42. TESFAYE, S, MALIK, R. AND WARD, J. D.: Vascular factors in diabetic neuropathy. Diabetologia 37: 847-854, 1994.
43. WARD, K. K, LOW, P. A, SCHMELZER, J. D. AND ZOCHODNE, D. W.: Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 112: 197-208, 1989.
44. WARNER, T. D, ALLCOCK, G. H. AND VANE, J. R.: Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br. J. Pharmacol. 112: 207-213, 1994.
45. WEBB, M. L, DICKENSON, K. E. J, DELANEY, C. L, LIU, E. C, SERAFINO, R., COHEN, R. B, MONSHIZADEGAN, H. AND MORELAND, S.: The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta. Biochem. Biophys. Res. Commun. 185: 887-892, 1992.
46. WHITE, R. E, CARRIER, G. O.: Enhanced vascular α-adrenergic neuroeffector system in diabetes: Importance of calcium. Am. J. Physiol. 255: H1036-H1042, 1988.
47. YANG, Z. H, RICHARD, V, VON SEGESSER, L, BAUER, E, STULZ, P, TURINA, M. AND LUSCHER, T. F.: Threshold concentration of endothelin 1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 82: 188-195, 1990.
48. YASUJIMA, M, ABE, K, KANAZAWA, M, YOSHIDA, K, KOHZUKI, M, TAKEUCHI, K., TSUNODA, K, KUDO, K, HIWATARI, M. AND SATO, T.: Antihypertensive effect of captopril and enalapril in endothelin infused rats. Tokhu J. Exp. Med. 163: 219-227, 1991.